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Summary
Objective: Resistance to anti-tuberculosis (anti-TB) drugs is becoming a major and alarming
threat in most regions worldwide.
Methods: This was a descriptive cross-sectional study at a tertiary hospital in Iran, using patient
medical records for 2000—2003. The findings were analyzed following the same framework as that
used for previous reports from this center.
Results: Among 1556 TB patients, drug susceptibility testing (DST) was performed for 548
culture-positive cases. Anti-TB drug resistance to both isoniazid and rifampin was identified
in 10 (2.8%) of the new TB cases (multidrug-resistant TB; MDR-TB). Any resistance was detected in
228 (41.6%), showing an increasing trend in both new and retreatment cases. The data analysis
revealed that drug-resistant TB had a statistically significant association with Afghan ethnicity,
age >65 years, and the type of disease (retreatment vs. new TB case) (p < 0.05). Also,
assessment of the drug resistance trends showed a significant increase in resistance to any
anti-TB agent, to isoniazid, and to streptomycin in new cases, and to all of the first-line anti-TB
drugs in retreatment patients.
Conclusions: There has been an increasing trend in drug resistance in recent years, particularly in
retreatment cases. Hence, revision of the national TB control program, reevaluation of the role of
the World Health Organization category II (CAT II) regimen, as well as the conducting of a
nationwide drug resistance survey, are recommended.
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In the scope of a remarkable improvement in the life expec-
tancy of the people of the world, along with the introduction
of chemotherapeutic measures, tuberculosis (TB) prevalence
witnessed a significant decline in the second half of the 20th
century. However, escalating HIV infection as well as negli-
gence in TB control have caused an increase in TB incidence
over the last decade, in both developing and developed
countries.1,2 Moreover, several other factors such as home-
lessness, poverty, lack of infrastructure in public health, and
inadequate access to health services have played an impor-
tant role in worsening the situation.3
TB is an important health problem in Iran, and the issue
has become even more so as a result of increasing drug-
resistant strains; drug resistance complicates efforts to con-
trol TB.4 It has been proved that patients infected with
strains resistant to rifampin (RIF) will experience a higher
failure rate with short-course 6-month chemotherapy.5,6
Multidrug-resistant TB (MDR-TB) patients, who show resis-
tance to both isoniazid (INH) and RIF require treatment for at
least 24 months.7 However, and despite this long and costly
treatment, a considerable number die of their disease and
many others have to endure the active and destructive form
of TB.8—10 Identifying the trends in drug resistance is one of
the important aspects in the assessment of TB epidemiologic
trends and TB control planning.11—13
In the first study performed at this center,14 drug resis-
tance was studied in culture-positive cases from September
1996 until March 2000. In another study, resistance to anti-TB
drugs was assessed from June 2003 to September 2004.15 In
the present study, we sought to determine drug resistance,
retrospectively, in the interval between the two aforemen-
tioned studies, using the same framework. The results
obtained and their association with sex, age, nationality,
and the type of disease were analyzed and compared with the
previous data.
Materials and methods
A descriptive retrospective study was conducted by making
use of the TB patient medical records of those hospitalized at
Masih Daneshvari Hospital, Tehran, Iran, the only national
referral center for drug-resistant TB in the country. The study
included a review of the records for the period March 2000—
February 2003, and the collection of information on personal
characteristics, sputum mycobacteriologic studies, and anti-
TB drug resistance detected by drug susceptibility testing
(DST) for first-line agents. The findings were analyzed with
SPSS 11.5, using the Chi-square test and Fisher’s exact test
for statistical significance assessments (the Armitage test
was used for trend evaluation in proportions). A p-value of
<0.05 was identified as statistically significant. A definitive
diagnosis of TB was made by positive smear and culture
results for Mycobacterium tuberculosis. New patients were
defined as those who had received either no anti-TB treat-
ment or less than 1 month of treatment. Retreatment
patients were defined as patients who had previously
received anti-TB treatment for at least 1 month, including
those with treatment failures and relapse.16 Resistance to
both INH and RIF was defined as multidrug resistance. Thestudy was carried out at the National Research Institute of
Tuberculosis and Lung Disease (NRITLD) at Masih Daneshvari
Hospital, the World Health Organization (WHO) collaborating
center in the Eastern Mediterranean Region (EMR) and the
sole national referral center for TB in Iran, housing the
National Mycobacteriologic Reference Laboratory (NRL).
The NRL is under the technical supervision of the Suprana-
tional Reference Laboratories of the Swedish Institute for
Infectious Disease Control (Solna, Sweden) and the Research
Institute of Tuberculosis of the Japan Anti-Tuberculosis Asso-
ciation (Tokyo, Japan).
Having documented the diagnosis with microscopic stu-
dies on the collected specimens (sputum, bronchoalveolar
lavage (BAL), pleural fluid, etc.), DST for INH, RIF, strepto-
mycin (SM), and ethambutol (EMB) was performed by the
proportion method on Lo¨wenstein—Jensen media at concen-
trations of 0.2 (INH), 40 (RIF), 4.0 (SM), and 2.0 (EMB) mg/ml.
Susceptibility to pyrazinamide (PZA; 900 and 1200 mg/ml)
was tested using a two-phase medium where the strain was
reported to be resistant to PZA if, on day 21, the proportion
of drug-resistant colonies was higher than the defined critical
proportion. The above-mentioned methods are discussed
elsewhere in more detail.17—19 DST against PZA was under-
taken for only some of the patients due to technical limita-
tions.
The scientific and ethics committee of the NRITLD in Iran
reviewed and approved the study protocol.
Results
Of the total number of 1556 patients diagnosed with TB, drug
susceptibility tests were performed for 548 culture-positive
cases. Of these, 317 (57.8%) were male; 357 (65.1%) were
Iranian, 186 (33.9%) were Afghan, and the other five cases
were of other nationalities.
The mean age of the subjects was 45.4 years ( 20.63).
The patients were categorized into three groups with the
following populations in each group: age <15 years: seven
cases (1.3%); age 15—65 years: 414 (75.5%); age >65 years:
127 (23.2%). With regard to the type of disease, 538 (98.2%)
were smear-positive pulmonary TB cases, while eight
patients (1.5%) had smear-negative pulmonary TB and two
(0.4%) had extrapulmonary TB. Three hundred and sixty-
three (66.2%) were new cases, while the other 185 (33.8%)
had been hospitalized as retreatment cases, including those
with treatment failure, incomplete treatment, or treatment
relapse (Table 1).
Of 548 cases for whom DST against first-line drugs was
performed, 152 (27.7%) showed resistance to INH; 119
(21.7%) were resistant to RIF, 174 (33.6%) were resistant to
SM, and 75 (13.7%) were resistant to EMB. Concomitant
resistance to both INH and RIF was reported in 106 (19.3%)
cases. Drug resistance rates in all patients as well as with
regards to disease type (new or retreatment case) are shown
in Table 2.
In this study, resistance to any drug and multidrug resis-
tance were analyzed against sex, age, and nationality. Any
drug resistance as well as MDR-TB was significantly associated
with age above 65 years. Furthermore, MDR-TB was signifi-
cantly higher in the non-Iranian group and in retreatment
cases ( p = 0.0001).
Table 1 Characteristics of the hospitalized patients for whom drug susceptibility testing was performed at Masih Daneshvari
Hospital, 2000—2003
Variable DST, n (%) Drug resistance, n (%) p-Value MDR-TB, n (%) p-Value
Sex
Male 317 (57.8) 148 (64.9) 0.005 70 (66.0) 0.058
Female 231 (42.2) 80 (35.1) 36 (34.0)
Age, years
<15 7 (1.3) 3 (1.3) 0.001 1 (0.9) 0.002
15—65 414 (75.5) 188 (82.5) 93 (87.7)
>65 127 (23.2) 37 (16.2) 12 (11.3)
Nationality
Iranian 357 (65.1) 129 (56.6) 0 50 (47.2) 0
Afghan 186 (33.9) 97 (42.5) 55 (51.9)
Other 5 (0.9) 2 (0.9) 1 (0.9)
Type of disease
S+C+ 538 (98.2) 224 (98.2) 0.9 105 (99.1) 0.4
SC+ 10 (1.8) 4 (1.8) 1 (0.9)
Type of patient
New case 363 (66.2) 98 (43.0) 0 10 (9.4) 0
Retreatment 185 (33.8) 130 (57.0) 96 (90.6)
Total 548 228 106
DST, drug susceptibility testing; MDR, multidrug-resistant; TB, tuberculosis; S+C+, smear-positive and culture-positive; SC+, smear-
negative and culture-positive.
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MDR-TB results from our study were compared to those of our
colleagues (Table 3; Figures 1 and 2).
Discussion
Overall, we found drug resistance to SM and INH was more
frequent than to the other agents. Similarly, in most other
studies, namely the first, second, and third rounds of the
WHO Global Projects as well as a similar study conducted in
Thailand, resistance to the two abovementioned agents hasTable 2 Drug resistance to anti-tuberculosis drugs in patients ho
vs. retreatment cases)
Variable New cases, n (%)
Any resistance INH (%) 42 (11.6)
Any resistance RIF (%) 14 (3.9)
Any resistance EMB (%) 11 (3.0)
Any resistance SM (%) 84 (23.1)
Only INH resistance (%) 9 (2.5)
Only RIF resistance (%) 1 (0.3)
Only EMB resistance (%) 1 (0.3)
Only SM resistance (%) 48 (13.2)
Resistance to one drug (%) 59 (16.3)
Resistance to two drugs (%) 29 (8.0)
Resistance to three drugs (%) 7 (1.9)
Resistance to four drugs (%) 3 (0.8)
MDR (%) 10 (2.8)
Total DST 363
INH, isoniazid; RIF, rifampin; EMB, ethambutol; SM, streptomycin; MDRbeen reported as more common compared to resistance to
other first-line drugs.20—22 However, other patterns of anti-TB
resistance also exist. In a 15-year surveillance in Saudi
Arabia, resistance to INH and EMB was more frequent than
to other first-line drugs.23
Analysis of the trend of drug resistance at our center
shows a significant increase in resistance to INH and EMB.
Yet, resistance to SM even in new cases is high (23.3%). This
can be attributed to the use of SM to treat brucellosis, a
disease that is endemic in Iran. In any case, this finding calls
into question the use of the WHO category II (CAT II) regimenspitalized at Masih Daneshvari Hospital, 2000—2003 (new cases
Retreatment cases, n (%) Total, n (%)
110 (59.5) 152 (27.7)
105 (56.8) 119 (21.7)
64 (34.6) 75 (13.7)
100 (54.1) 184 (33.6)
4 (2.2) 13 (2.4)
5 (2.7) 6 (1.1)
2 (1.1) 3 (0.5)
9 (4.9) 57 (10.4)
20 (10.8) 79 (14.4)
28 (15.1) 57 (10.4)
25 (13.5) 32 (5.8)
57 (30.8) 60 (10.9)
96 (51.9) 106 (19.3)
185 548
, multidrug-resistant; DST, drug susceptibility testing.
Table 3 Anti-tuberculosis drug resistance trends in TB patients at Masih Daneshvari Hospital
Variable New cases Retreatment cases
1996—2000a 2000—2003b 2003—2004c p-Value 1996—2000 2000—2003 2003—2004 p-Value
Total tested 187 363 196 86 185 68
Any resistance (%) 26 26.9 39 0.004d 56 70.2 79 0.001d
Any resistance INH (%) 15 11.6 23 0.026d 55 59.9 71 0.05d
Any resistance RIF (%) 6.5 3.9 6 0.849 43 56.8 60 0.026d
Any resistance EMB (%) 5.5 3 4 0.464 20 34.6 41 0.0048d
Any resistance SM (%) 13 23.3 27 0.0009d 18 54.1 65 0.000d
MDR (%) 3 2.8 2.6 0.812 48.1 51.9 58 0.04d
INH, isoniazid; RIF, rifampin; EMB, ethambutol; SM, streptomycin; MDR, multidrug-resistant.
a Mansouri et al.14
b Present study.
c Mirsaeidi et al.15
d Increasing trend.
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countries like Iran.
MDR-TB in retreatment patients varies from 30% to 80% in
different regions.24 As reported by theWHOGlobal Project in
79 countries worldwide over 1999—2002, MDR-TB was found
in 1.1% of new cases and 6.9% of retreatment patients.21 In
the EMR, MDR prevalence in 2004 was 2% for new cases and
29.4% for retreatment cases.20 In this study, MDR-TB was
found in 2.8% of new cases, while 51.9% of retreatment cases
were proved to beMDR-TB; this shows a higher percentage of
MDR-TB in Iran, particularly in retreatment cases, compared
to EMR data. Surprisingly, our study noted that MDR-TB
prevalence is significantly higher in Afghan patients,
patients aged above 65 years, and retreatment cases
(Table 1).
The relationship between history of receiving anti-TB
treatment and drug resistance has been clearly described
in several studies.20,22,25,26 However, the association
between drug resistance and immigrant cases has not been
consistently shown, and in some reports no difference
between aboriginals and immigrants with regard to drug
resistance has been found.23,27 However, Afghan patients
consist of more than half of our MDR-TB cases in Iran,
reflecting insufficient health services and surveillance infra-
structure in their country.28 The increasing resistance to INH,
which is one of the main agents in TB treatment, is an
alarming sign and indicates further transmission of resistant
strains in the community.Figure 1 Anti-tuberculosis drug resistance trends in new case
TB patients at Masih Daneshvari Hospital.The trend in drug resistance against all first-line drugs
shows a significant increase. This remarkable percentage of
drug resistance, along with a significant difference in drug
resistance between new cases and retreatment patients,
supports the idea of inefficiency in TB control programs
and irregular/improper anti-TB drug use during recent years,
which have led to accumulation and multiplication of resis-
tant strains. Notably, resistance to the other cornerstone of
anti-TB therapy, RIF, did not show an increase in new cases,
while in contrast, resistance to this agent was significantly
elevated in retreatment cases. This reveals the fact that with
irregular treatment and in the presence of INH resistance,
virtual monotherapy results in resistance to other agents as
well.29
With regard to our findings, mycobacteriologic cultures
and DST should be performed for all smear-positive treat-
ment failures so that one can determine the suitable indivi-
dualized regimen for the patient, and consequently prevent
further resistance development. In addition, this will lead to
lower morbidity and mortality in patients. In this regard, the
WHO CAT II regimen should undergo a practical revision,
especially for countries with high rates of resistance to
SM. Also, the strategy of using fixed drug combination
(FDC) therapy may be a good solution for reducing drug
resistance, by preventing irregular treatments, improving
patient compliance, as well as preventing monotherapy.30,31
However, our study encountered some limitations. In the
period over which the study was conducted, DST for PZA wasFigure 2 Anti-tuberculosis drug resistance trends in retreat-
ment case TB patients at Masih Daneshvari Hospital.
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only studied culture-positive cases for drug resistance.
Assignment of the cases to the new case or retreatment
categories was based upon the information given by the
patients and may not have been accurate. On the other
hand, the population on which this study was performed
had presented to our referral center. Though new TB cases
made up more than 65% of the patients, our data may not
necessarily be representative of the national population
especially with regard to new cases, as only patients with
more serious conditions may have presented to our center. As
our center is the sole national referral center for TB treat-
ment failures, its findings may indicate the general popula-
tion information for previously retreated patients. A
nationwide survey of drug resistance is required in order
to attain a more precise estimation.
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